Related Experiment Videos
[Erectile dysfunction: clinical course with intracavernous PGE1]
J L Ruiz Rubio1, A Paez Borda, R Romero Cagigal
1Servicio de Urología, Hospital Universitario de Getafe, Madrid, España.
Archivos Espanoles De Urologia
|April 1, 1996
Summary
Prostaglandin E1 (PGE1) therapy for erectile dysfunction showed varied outcomes in a self-injection program. Local pain was linked to shorter treatment duration, with some patients requiring alternative therapies.
Area of Science:
- Urology
- Andrology
Background:
- Erectile dysfunction (ED) affects a significant number of men, impacting quality of life.
- Self-injection therapy with vasoactive agents is a treatment option for ED.
Purpose of the Study:
- To evaluate the outcomes of Prostaglandin E1 (PGE1) therapy in an erectile dysfunction (ED) self-injection program.
- To assess patient adherence, response rates, and adverse events associated with PGE1 self-injection.
Main Methods:
- Sixty-six patients with ED were enrolled in a PGE1 self-injection program.
- Exclusion criteria included severe systemic diseases and hormonal/psychological disorders.
- Dose adjustment and patient instruction were key components of the methodology. Statistical analysis utilized chi-square and Student's t-test.
Main Results:
- The mean follow-up period was 9.8 months.
- 37% of patients withdrew from the program.
- 9% required alternative treatments due to pain or inadequate response; 5 patients received penile implants and 1 a vacuum erection device.
Conclusions:
- Local pain was associated with a shorter treatment duration in the PGE1 self-injection program.
- A minority of patients did not respond adequately to PGE1, necessitating alternative therapeutic approaches.